LT2882440T - Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį - Google Patents

Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį

Info

Publication number
LT2882440T
LT2882440T LTEP13748243.6T LT13748243T LT2882440T LT 2882440 T LT2882440 T LT 2882440T LT 13748243 T LT13748243 T LT 13748243T LT 2882440 T LT2882440 T LT 2882440T
Authority
LT
Lithuania
Prior art keywords
inhibitor
pi3k
optionally
alpha
pharmaceutical combinations
Prior art date
Application number
LTEP13748243.6T
Other languages
English (en)
Lithuanian (lt)
Inventor
Giordano Caponigro
Darrin Stuart
Laure Moutouh-De Parseval
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2882440(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT2882440T publication Critical patent/LT2882440T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP13748243.6T 2012-08-07 2013-08-05 Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį LT2882440T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (1)

Publication Number Publication Date
LT2882440T true LT2882440T (lt) 2019-04-25

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13748243.6T LT2882440T (lt) 2012-08-07 2013-08-05 Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį

Country Status (39)

Country Link
US (1) US9474754B2 (cg-RX-API-DMAC7.html)
EP (2) EP3574904A1 (cg-RX-API-DMAC7.html)
JP (3) JP6342396B2 (cg-RX-API-DMAC7.html)
KR (1) KR102112885B1 (cg-RX-API-DMAC7.html)
CN (1) CN104519887B (cg-RX-API-DMAC7.html)
AR (1) AR092045A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013299841B8 (cg-RX-API-DMAC7.html)
CA (1) CA2879548C (cg-RX-API-DMAC7.html)
CL (1) CL2015000294A1 (cg-RX-API-DMAC7.html)
CO (1) CO7200273A2 (cg-RX-API-DMAC7.html)
CY (1) CY1122143T1 (cg-RX-API-DMAC7.html)
DK (1) DK2882440T3 (cg-RX-API-DMAC7.html)
EA (1) EA028420B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15008695A (cg-RX-API-DMAC7.html)
ES (1) ES2717911T3 (cg-RX-API-DMAC7.html)
GT (1) GT201500025A (cg-RX-API-DMAC7.html)
HK (1) HK1211831A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20190537T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042877T2 (cg-RX-API-DMAC7.html)
IL (1) IL236934B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00450A (cg-RX-API-DMAC7.html)
JO (1) JOP20130236B1 (cg-RX-API-DMAC7.html)
LT (1) LT2882440T (cg-RX-API-DMAC7.html)
MA (1) MA37829A1 (cg-RX-API-DMAC7.html)
MX (1) MX359403B (cg-RX-API-DMAC7.html)
MY (1) MY176031A (cg-RX-API-DMAC7.html)
NZ (1) NZ703940A (cg-RX-API-DMAC7.html)
PE (2) PE20150673A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500246B1 (cg-RX-API-DMAC7.html)
PL (1) PL2882440T3 (cg-RX-API-DMAC7.html)
PT (1) PT2882440T (cg-RX-API-DMAC7.html)
RS (1) RS58734B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201500321YA (cg-RX-API-DMAC7.html)
SI (1) SI2882440T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000027A1 (cg-RX-API-DMAC7.html)
TR (1) TR201904980T4 (cg-RX-API-DMAC7.html)
TW (1) TWI607754B (cg-RX-API-DMAC7.html)
UA (1) UA115786C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014025688A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013299841B8 (en) * 2012-08-07 2017-01-05 Array Biopharma Inc. Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
JP2018526375A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー 組み合わせ療法
US10328065B2 (en) 2015-08-28 2019-06-25 Novartis Ag Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017210538A1 (en) * 2016-06-03 2017-12-07 Giordano Caponigro Pharmaceutical combinations
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
DK3618875T3 (da) 2017-05-02 2023-07-10 Novartis Ag Kombinationsterapi omfattende en raf-inhibitor og trametinib
WO2019026007A1 (en) * 2017-08-03 2019-02-07 Novartis Ag THERAPEUTIC ASSOCIATION OF THIRD GENERATION TYFRSINE KINASE INHIBITOR AND RAF INHIBITOR
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
JPWO2023145530A1 (cg-RX-API-DMAC7.html) * 2022-01-27 2023-08-03
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
CN120359031A (zh) * 2022-09-26 2025-07-22 马布可尔公司 用于治疗癌症的b-raf抑制剂和抗egfr抗体的组合
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AU2010289794B2 (en) * 2009-08-24 2014-10-02 Genentech, Inc. Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
JP2013507442A (ja) * 2009-10-12 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
TR201802943T4 (tr) * 2010-11-08 2018-03-21 Novartis Ag (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı.
WO2013070998A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
CA2855243C (en) * 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
AU2013299841B8 (en) * 2012-08-07 2017-01-05 Array Biopharma Inc. Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor

Also Published As

Publication number Publication date
AU2013299841A8 (en) 2017-01-05
PL2882440T3 (pl) 2019-07-31
GT201500025A (es) 2017-09-28
UA115786C2 (uk) 2017-12-26
TN2015000027A1 (en) 2016-06-29
TWI607754B (zh) 2017-12-11
CN104519887B (zh) 2017-06-27
ES2717911T3 (es) 2019-06-26
CA2879548C (en) 2020-07-21
EA201590332A1 (ru) 2015-06-30
IL236934B (en) 2018-11-29
JP2018109022A (ja) 2018-07-12
AR092045A1 (es) 2015-03-18
JP6974669B2 (ja) 2021-12-01
PT2882440T (pt) 2019-04-23
CO7200273A2 (es) 2015-02-27
MY176031A (en) 2020-07-22
US9474754B2 (en) 2016-10-25
CY1122143T1 (el) 2020-11-25
DK2882440T3 (da) 2019-05-06
MX2015001732A (es) 2015-06-03
JP2020019780A (ja) 2020-02-06
RS58734B1 (sr) 2019-06-28
EP2882440B1 (en) 2019-02-27
AU2013299841A1 (en) 2015-02-12
US20150265616A1 (en) 2015-09-24
SI2882440T1 (sl) 2019-05-31
MX359403B (es) 2018-09-26
CA2879548A1 (en) 2014-02-13
EP3574904A1 (en) 2019-12-04
ECSP15008695A (es) 2019-03-29
JP2015524472A (ja) 2015-08-24
PE20191655A1 (es) 2019-11-07
PH12015500246A1 (en) 2015-03-30
JP6595024B2 (ja) 2019-10-23
AU2013299841B2 (en) 2016-11-24
PH12015500246B1 (en) 2015-03-30
AU2013299841B8 (en) 2017-01-05
HK1204976A1 (en) 2015-12-11
IN2015DN00450A (cg-RX-API-DMAC7.html) 2015-06-26
JOP20130236B1 (ar) 2021-08-17
EP2882440A1 (en) 2015-06-17
TR201904980T4 (tr) 2019-05-21
BR112015002384A2 (pt) 2017-07-04
KR102112885B1 (ko) 2020-05-19
JP6342396B2 (ja) 2018-06-13
PE20150673A1 (es) 2015-05-20
MA37829A1 (fr) 2017-01-31
NZ703940A (en) 2018-04-27
BR112015002384A8 (pt) 2023-01-31
CL2015000294A1 (es) 2015-05-08
CN104519887A (zh) 2015-04-15
WO2014025688A1 (en) 2014-02-13
HRP20190537T1 (hr) 2019-06-28
TW201410247A (zh) 2014-03-16
SG11201500321YA (en) 2015-04-29
KR20150040905A (ko) 2015-04-15
HUE042877T2 (hu) 2019-07-29
EA028420B1 (ru) 2017-11-30
HK1211831A1 (zh) 2016-06-03

Similar Documents

Publication Publication Date Title
SG11201500321YA (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
GB201218801D0 (en) Device,method and software
IL234850B (en) Rapid aneuploidy detection
EP2821748A4 (en) DEVICE FOR FINDING A BEACH AND METHOD FOR FINDING A BEACH
EP2868008A4 (en) SIMULTANEOUS TRANSMISSION AND RECEPTION
EP2676643A4 (en) EXCREMENT HANDLING DEVICE AND ASSOCIATED METHOD
HUE036907T2 (hu) Egyidejû adás és vétel
PL2831055T3 (pl) Zdolne do polimeryzacji alkilideno-1,3-dioksolan-2-ony i ich zastosowanie
GB201906245D0 (en) A method and device
EP2903772A4 (en) MATERIALS, METHODS AND DEVICES FOR CONNECTING LINES
SG11201404996RA (en) Noodle-steaming method and noodle-steaming device
IL237926A0 (en) Combinations and their uses
EP2806084A4 (en) SHAPING DEVICE AND CONSTRUCTION PROCESS WITH THE FORMING DEVICE
SG10201604887RA (en) Mixing device, discharge device provided therewith, and discharge method
ZA201206179B (en) Software fingerprinting
SG11201501033UA (en) A device and a method for anastomosis
EP2806020A4 (en) PERSON SELECTION DEVICE AND PERSON SELECTION PROCEDURE
IL235919A0 (en) inhibitors of fbxo3
SG11201505068RA (en) Drawing device and drawing method
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
EP2836857A4 (en) COUPLER, PROCESS AND APPLICATIONS
EP2850785A4 (en) METHODS AND DEVICES FOR INITIATING A COMPLEMENTARY APPLICATION
AU2013200291A1 (en) Methods and devices for context set selection
EP2821964A4 (en) COLOR SCALE DETERMINING DEVICE, COLOR SCANNING DETERMINING METHOD, AND COLOR SCANNING DETERMINING PROGRAM
EP2858280A4 (en) METHOD OF ESTABLISHING ROADS AND DEVICE THEREOF